What Omeprazol STADA treats: main uses and benefits

Omeprazol STADA is a medication used to manage conditions related to excessive stomach acid production. It belongs to a class of drugs known as proton pump inhibitors (PPIs), which work by reducing the amount of acid produced by the glands in the lining of the stomach.

Primary Uses in Adults

In adult patients, this medication is typically used to manage several digestive conditions:

• Gastroesophageal Reflux Disease (GERD): This is a condition where acid from the stomach escapes into the esophagus, causing inflammation, pain, and heartburn.
• Gastric and Duodenal Ulcers: It is used to treat ulcers occurring in the upper part of the intestine or the stomach itself.
• Helicobacter pylori Infection: When used in combination with appropriate antibiotics, it helps eliminate this bacterium to allow for the healing of associated duodenal ulcers.
• Zollinger-Ellison Syndrome: This is a rare condition where the stomach produces an excessive amount of acid due to a growth in the pancreas or small intestine.
• NSAID-Associated Ulcers: It may be used to treat or prevent ulcers that can develop as a side effect of taking non-steroidal anti-inflammatory drugs (NSAIDs).

Pediatric Use

In children and adolescents, the application of this medication is generally focused on specific reflux-related conditions:

• GERD in Children over 1 year: It is used to treat the symptoms of acid reflux and inflammation of the esophagus.
• Helicobacter pylori Infection in Children over 4 years: Similar to adults, it is used as part of a combination therapy to treat ulcers caused by this bacterial infection.

Expected Benefits

The primary benefit of this treatment is the significant reduction of gastric acidity. By lowering acid levels, the medication allows the esophageal and gastric linings to heal, reduces the frequency of heartburn, and prevents further damage to the digestive tract caused by acid erosion.

Regulatory References

1. NIH MedlinePlus overview

Populations for whom use is allowed (as stated in label):

• Adults are permitted for use across all labeled indications.
• Adolescents and children (aged 1 year and above, weighing 10 kg or more) are permitted for specific indications like Gastroesophageal Reflux Disease (GERD).

Populations for whom use is not recommended (if applicable):

• Pediatric patients less than 1 year of age are generally not recommended for use, as safety and effectiveness are officially not established for most indications.

Populations for whom use is contraindicated:

• Patients with known hypersensitivity to the active substance Omeprazole or any substituted benzimidazoles.
• Patients receiving concomitant treatment with the antiviral agent Nelfinavir.

Age-related eligibility rules:

• Approved use begins at 1 month of age for limited indications, based on weight. Use is fully established in older adults with no specific age-based dose adjustment required.

Condition-specific eligibility rules:

• Use is restricted in patients with severe hepatic impairment, where special consideration or dose modification may be required due to altered drug exposure.
• Initiation of therapy in adults requires the exclusion of gastric malignancy.

Pregnancy and lactation eligibility status (if explicitly documented):

• Use during pregnancy is generally considered acceptable when clinically necessary. The drug is excreted into human milk, but is often considered a preferred choice during breastfeeding.

Eligibility-related restrictions:

• Patients with risk factors for reduced Vitamin B12 absorption require caution during long-term therapy.

---

Official eligibility statements:

• Contraindicated in patients with hypersensitivity or concomitant use of Nelfinavir.
• Use is not established in pediatric patients less than 1 year of age.
• Use in patients with severe hepatic impairment requires special consideration.

Connection to the overall eligibility profile (2–4 sentences):

Official regulatory documents define who can and cannot use Omeprazol STADA by establishing non-negotiable contraindications based on drug hypersensitivity or concurrent medication. They also set explicit age and weight limits for pediatric use, noting that safety is not established below 1 year of age for most indications. Conditional eligibility applies to those with severe hepatic impairment, requiring consideration, while full eligibility is confirmed for older adults.

Interactions with other medicines and products

Omeprazole, the active ingredient in Omeprazol STADA, has officially documented interaction patterns based on its two primary mechanisms: the suppression of gastric acid and the inhibition of the CYP2C19 metabolic enzyme.

---

Documented Exposure-Altering Interactions

Co-administration with Omeprazole may alter the plasma concentrations of certain medicines, necessitating close regulatory attention. Drugs that rely on acidic gastric pH for absorption, such as ketoconazole and iron salts, may have their bioavailability reduced due to Omeprazole's acid-suppressing effect. Conversely, Omeprazole's inhibition of CYP2C19 can lead to increased systemic exposure and potential toxicity for substrates like diazepam and phenytoin, as documented in prescribing information.

---

Official Restrictions and Contraindications

Official regulatory documents define strict co-administration rules. The use of Omeprazole is contraindicated with the antiretroviral agent rilpivirine due to the significant reduction in rilpivirine's plasma levels. Furthermore, Omeprazole is documented to reduce the formation of the active metabolite of the antiplatelet drug clopidogrel, thereby diminishing its intended activity, a combination generally avoided. Caution is also specified for co-administration with warfarin, where an increase in the International Normalized Ratio (INR) may occur. In addition, treatment should be temporarily stopped at least 14 days before assessing diagnostic Chromogranin A (CgA) levels to prevent test interference.

Omeprazol STADA is classified as a proton pump inhibitor (PPI) that functions by irreversibly suppressing the final step of acid secretion in the gastric parietal cells. The mechanism involves two phases: acid-dependent activation and enzyme inhibition. Omeprazol is administered as an inactive prodrug which accumulates selectively within the highly acidic secretory canaliculi of the parietal cell

. In this environment, the prodrug is converted into its active sulfenamide form. This selective activation limits the active compound primarily to the site of action. The active form then targets the H^+/ K^+-ATPase enzyme, known as the gastric proton pump. It forms a stable covalent bond with specific cysteine residues on the enzyme's structure. This irreversible modification permanently blocks the pump's capacity to exchange hydrogen ions ( H^+) for potassium ions ( K^+), thus preventing the efflux of acid into the stomach lumen. The resulting physiological effect is a reduction in both basal and stimulated acid secretion, irrespective of the signal cascade that activated the proton pump.

How to Use Omeprazol STADA: Administration Guidelines

The usage of omeprazole involves specific protocols detailing the route, dosage ranges, frequency, and administration conditions. The primary route of administration is oral, utilizing hard gastro-resistant capsules. When oral intake is restricted, an intravenous (IV) solution may be administered.

---

Dosing and Frequency

Omeprazole is typically taken once daily. The standard dose range for most acute and maintenance conditions is 10 mg to 40 mg once daily. An exception to the frequency is for H. pylori eradication, which requires 20 mg twice daily, and high-dose regimens for Zollinger-Ellison Syndrome, where doses exceeding 80 mg must be divided and administered twice daily.

---

Administration Requirements

Detail	Instruction
Timing in relation to meals	Must generally be taken before eating (e.g., before breakfast).
Capsule integrity	The capsule must not be crushed, chewed, or opened to preserve the gastro-resistant coating.
Alternative administration	Contents of the capsule may be mixed with a non-acidic liquid or soft food like applesauce and swallowed immediately if the patient cannot swallow the capsule whole.

---

Population-Specific Adjustments

Dosing requires modification for patients with hepatic impairment, with a lower daily dose of 10 mg to 20 mg often considered sufficient. Conversely, dose adjustments are typically not required for renal impairment or for older adults (over 65 years).

Research Evidence / Overview of Studies for Omeprazole STADA

Omeprazole was studied for use in a variety of conditions characterized by fluctuating or episodic manifestations linked to stomach acid. The research comes from a mix of clinical trials, where people are randomly assigned to different treatment groups, and observational studies, which look at patterns in large groups of people over time. Studies help show what has been observed so far in the populations examined.

---

Gastroesophageal Reflux Disease (GERD) and Esophagitis

What was studied: Research was evaluated for omeprazole in individuals with GERD, often called reflux disease, and related conditions like erosive esophagitis. These studies were used in research exploring how symptoms change over time, particularly focusing on outcomes related to physical discomfort like heartburn and regurgitation. The trials often observed responses over defined time intervals, such as four to eight weeks.

What was found: The data show patterns related to changes in the condition of the esophageal tissue and in outcomes related to physical discomfort reported by participants. In short-term studies, the findings describe patterns observed in the studies where individuals reported changes in the frequency and severity of their symptoms. For individuals with more functional limitations associated with esophagitis, studies explored whether continued use was associated with changes in the return of symptoms.

Uncertainty and Limitations: While short-term research is widely available, evidence is limited on the full range of long-term outcomes, as many randomized studies follow-up durations were limited. The research does not determine whether an individual will respond similarly, and for some people, the symptoms may persist even with treatment.

---

Ulcers (Gastric and Duodenal)

What was studied: Omeprazole was studied for outcomes related to the healing of both gastric and duodenal ulcers. This includes ulcers associated with H. pylori bacteria and those linked to the use of non-steroidal anti-inflammatory drugs (NSAIDs). The research applied in studies examining patient-reported experiences of discomfort and focused on outcomes linked to inflammatory or irritative states.

What was found: Clinical trials explored omeprazole, often in combination with antibiotics for H. pylori-related ulcers. The data show patterns related to changes in the condition of ulcers. For ulcers not related to H. pylori, research examined omeprazole in relation to patterns observed during ulcer episodes and for changes in the recurrence of episodes. Evidence suggests omeprazole was associated with changes in the likelihood of new ulcer episodes in people who need to continue taking NSAIDs.

Uncertainty and Limitations: The evidence related to combined treatment for H. pylori eradication was extensively studied; however, for some specific groups, the data for certain groups remain insufficient. Comparative evidence against some newer therapies is lacking, and while patterns of ulcer recurrence were observed in relation to long-term use in some studies, certainty remains low for certain long-term outcomes.

Common questions about Omeprazol STADA (FAQ)

---

Q: Is Omeprazol STADA considered the same as other omeprazole brands?

Omeprazol STADA contains the active ingredient omeprazole. Regulatory authorities require that generic omeprazole products demonstrate bioequivalence to the reference product. This means the medicine is required to be absorbed and work in the body in a way that is similar to other versions of omeprazole.

---

Q: Does Omeprazol STADA contain gluten or lactose?

Omeprazole formulations often contain excipients such as lactose or sucrose. Official product information states that patients with certain hereditary sugar intolerances should review the Patient Information Leaflet or discuss the full composition of the capsule with a healthcare professional.

---

Q: Can Omeprazol STADA cause headaches or dizziness?

According to official product information, headache is listed as a common side effect, meaning it may affect up to 1 in 10 people. Dizziness is listed as an uncommon side effect, which may affect up to 1 in 100 people.

---

Q: Are there any common digestive side effects noted for Omeprazol STADA?

Yes, regulatory documents list several common digestive side effects that may affect up to 1 in 10 people. These effects include abdominal pain, constipation, diarrhoea, flatulence, and feeling sick (nausea or vomiting). The majority of documented adverse reactions relate to the gastrointestinal system.

---

Q: How quickly should I expect Omeprazol STADA to start working?

The onset of the acid-reducing effect begins within one hour after the medicine is taken orally. The maximum effect on acid reduction is generally reached within two hours. Official documents state that consistent daily dosing increases the full inhibitory effect over the first four days of treatment.

---

Q: Is it normal to feel a difference in stomach acid right away?

Studies indicate that the medicine begins to reduce acid secretion within an hour of dosing, with maximum effect occurring within two hours. However, the sustained, full inhibitory effect is known to increase with repeated daily dosing over the initial four days of therapy.

---

Q: How long does the effect of one dose of Omeprazol STADA usually last?

The inhibitory effect of the medicine on the secretion of acid can last up to 72 hours, which is longer than the time the drug stays in the bloodstream. Due to this sustained effect, the medicine is typically administered once daily.

---

Q: Can taking Omeprazol STADA affect the absorption of vitamins or minerals?

Official warnings state that Omeprazole, like all acid-blocking medicines, may reduce the absorption of vitamin B12 (cyanocobalamin) during long-term therapy. This specific risk is noted due to reduced stomach acid being necessary for B12 absorption. Long-term use is also associated with deficiencies in magnesium.

---

Q: Is Omeprazol STADA safe to use if I have kidney problems?

Dose adjustment is typically not required for individuals with impaired kidney function. However, regulatory warnings specify that the medication may need to be stopped if a rare type of kidney inflammation (tubulointerstitial nephritis) is suspected.

---

Q: Does Omeprazol STADA have a risk of affecting bone density?

Long-term and high-dose use of proton pump inhibitor therapy has been associated with an increased risk of bone fractures, specifically of the hip, wrist, or spine. This risk is associated with the drug class and the duration of use.

---

Q: Does Omeprazol STADA affect liver function?

Official documents note that an increase in liver enzymes is an uncommon side effect, and rare side effects include hepatitis. Caution and special dose considerations are advised for patients with pre-existing severe liver impairment.

---

Q: What are the official usage guidelines for taking Omeprazol STADA?

Official usage guidelines specify the recommended treatment duration, such as 2 to 8 weeks for certain acute conditions. These guidelines also cover the administration schedule and the individual dose adjustments necessary for maintenance therapy or specific syndromes.

---

Q: Can Omeprazol STADA change the taste of food?

Taste disturbance is listed in official documents as a rare side effect, meaning it may affect up to 1 in 1,000 people. This change is classified under nervous system disorders.

---

Q: Is Omeprazol STADA meant to be taken every day?

The medicine is typically prescribed to be taken once daily for the entire duration of the course as determined by a healthcare provider. The frequency is typically once daily, although specific medical conditions may require a different frequency, as determined by a healthcare provider.

---

Q: Do studies suggest Omeprazol STADA works for all types of reflux?

The medicine is officially indicated for the treatment of symptoms associated with Gastro-oesophageal Reflux Disease (GERD). These indications cover the treatment of symptoms like heartburn and acid regurgitation, and for healing reflux oesophagitis. Official documents do not make specific claims about effectiveness against all possible forms of reflux.

---

Q: Can Omeprazol STADA cause dry mouth?

Dry mouth is listed as a rare side effect in official product information, which may affect up to 1 in 1,000 people. This effect is classified under gastrointestinal disorders.

---

Q: Does Omeprazol STADA help with symptoms other than heartburn?

Yes, regulatory documents indicate the medicine is used for a variety of conditions beyond heartburn. These include the healing of stomach and duodenal ulcers, maintaining the healing of reflux oesophagitis, and treating the symptoms of Zollinger-Ellison Syndrome.

---

Q: Do official documents mention any effects of Omeprazol STADA on cognitive function?

Official documents list various psychiatric and nervous system side effects. Uncommon effects include insomnia, while rare effects include agitation, confusion, and depression. Very rare effects such as aggression and hallucinations are also listed, which are all related to mental status.

---

Q: Are there any known interactions between Omeprazol STADA and herbal supplements?

Official prescribing information notes a specific interaction with the herbal supplement St. John's Wort (Hypericum perforatum). This supplement may reduce the concentration of omeprazole in the body. The drug label emphasizes the importance of sharing information about all herbal supplements being taken with a healthcare provider.

Storage and Disposal Conditions for Omeprazol STADA

Official regulatory documents specify mandatory conditions for the storage and handling of Omeprazol STADA hard gastro-resistant capsules to ensure product stability and integrity.

---

Storage Requirements

Omeprazol STADA must be stored at a temperature not exceeding 25°C. The medicine is required to be kept in the original package at all times to ensure it is protected from both light and moisture. Maintaining this packaging integrity is essential for the product's stability. For household safety, the medicine must be stored out of the sight and reach of children.

---

Disposal Instructions

Any unused or expired Omeprazol STADA must be handled as pharmaceutical waste. The product must not be thrown away via wastewater or standard household trash. Instead, unused medicine must be disposed of in accordance with local regulatory requirements for pharmaceutical products.